Rajesh Krishnan - 25 May 2021 Form 3 Insider Report for Oncternal Therapeutics, Inc.

Role
Chief Technology Officer
Signature
/s/Chase C. Leavitt, Attorney-in-fact
Issuer symbol
N/A
Transactions as of
25 May 2021
Net transactions value
$0
Form type
3
Filing time
27 May 2021, 18:06:45 UTC
Next filing
05 Jan 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ONCT Stock Options 25 May 2021 Common Stock 75,000 $4.30 Direct F1
holding ONCT Stock Options 25 May 2021 Common Stock 40,000 $5.76 Direct F2
holding ONCT Stock Options 25 May 2021 Common Stock 12,470 $3.33 Direct F3
holding ONCT Stock Options 25 May 2021 Common Stock 160,000 $4.59 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 One quarter of the shares subject to the stock options vested on August 12, 2020, and the remaining shares subject to the option vest in 36 equal monthly installments over the three-year period thereafter, subject to the Reporting Person's continued employment or service with the Issuer on each such date.
F2 One quarter of the shares subject to the stock options vested on September 12, 2020, and the remaining shares subject to the option vest in 36 equal monthly installments over the three-year period thereafter, subject to the Reporting Person's continued employment or service with the Issuer on each such date.
F3 Shares subject to the stock options vested in full on March 17, 2020.
F4 One quarter of the shares subject to the stock options vest on January 6, 2022, and the remaining shares subject to the option vest in 36 equal monthly installments over the three-year period thereafter, subject to the Reporting Person's continued employment or service with the Issuer on each such date.

Remarks:

Exhibit 24 - Power of Attorney